|Chemical and physical data|
|Molar mass||243.249 g/mol g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Manifaxine (GW-320,659) is a drug developed by GlaxoSmithKline through structural modification of radafaxine, one of the major active metabolites of bupropion. It acts as a norepinephrine-dopamine reuptake inhibitor (NDRI). It was researched for treatment of ADHD and obesity and was shown to be safe, reasonably effective and well tolerated for both applications, but no results have been reported following these initial trials and its current status is unclear.
- DeVeaugh-Geiss J, Conners CK, Sarkis EH, Winner PK, Ginsberg LD, Hemphill JM, Laurenza A, Barrows CE, Webster CJ, Stotka CJ, Asgharnejad M. GW320659 for the treatment of attention-deficit/hyperactivity disorder in children. Journal of the American Academy of Child and Adolescent Psychiatry. 2002 Aug;41(8):914-20. PMID 12162627
- Spraggs CF, Pillai SG, Dow D, Douglas C, McCarthy L, Manasco PK, Stubbins M, Roses AD. Pharmacogenetics and obesity: common gene variants influence weight loss response of the norepinephrine/dopamine transporter inhibitor GW320659 in obese subjects. Pharmacogenetics and Genomics. 2005 Dec;15(12):883-9. PMID 16272960
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|